AFFILIN Trademark

Trademark Overview


On Tuesday, July 29, 2014, a trademark application was filed for AFFILIN with the United States Patent and Trademark Office. The USPTO has given the AFFILIN trademark a serial number of 79155885. The federal status of this trademark filing is PARTIAL SECTION 71 ACCEPTED as of Tuesday, May 17, 2022. This trademark is owned by Scil Proteins GmbH. The AFFILIN trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:

[Pharmaceutical and veterinary preparations for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological ...

[Chemicals used in industry and science, in particular comprising antibody-like proteins or artificial proteins, except finishing agents for the preparation of synthetic and natural fibres; polypeptides and proteins for industrial purposes, including the manufacturing and purification of proteins, polypeptides, chemicals and other substances; diagnostic and analytic preparations for scientific or research use, not for medical or veterinary use; chemical reagents for analysis in laboratories, not for medical or veterinary use; biological tissue cultures for laboratories, not for medical or veterinary use; biological tissue cultures for laboratory analysis and diagnostics other than for medical or veterinary purposes]

Scientific and industrial research in particular in the biological, biochemical, diagnostic and pharmaceutical fields; biochemistry and pharmaceutical laboratory services; scientific and technological services, namely, scientific research, analysis, testing, in particular in the biological, biochemical, diagnostic and pharmaceutical fields; industrial research and analysis, namely, services in development of biological, biochemical, pharmaceutical and diagnostic products; research for the identification and further development of biological, biochemical, pharmaceutical and diagnostic products
affilin

General Information


Serial Number79155885
Word MarkAFFILIN
Filing DateTuesday, July 29, 2014
Status707 - PARTIAL SECTION 71 ACCEPTED
Status DateTuesday, May 17, 2022
Registration Number4838850
Registration DateTuesday, October 27, 2015
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 11, 2015

Trademark Statements


Goods and Services[Pharmaceutical and veterinary preparations for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis; medical therapeutic agents for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis; biochemical therapeutic agents for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis, except preparations containing theophylline; diagnostic and analytical preparations for medical and veterinary use; biological and chemical diagnostic reagents for medical use]
Goods and Services[Chemicals used in industry and science, in particular comprising antibody-like proteins or artificial proteins, except finishing agents for the preparation of synthetic and natural fibres; polypeptides and proteins for industrial purposes, including the manufacturing and purification of proteins, polypeptides, chemicals and other substances; diagnostic and analytic preparations for scientific or research use, not for medical or veterinary use; chemical reagents for analysis in laboratories, not for medical or veterinary use; biological tissue cultures for laboratories, not for medical or veterinary use; biological tissue cultures for laboratory analysis and diagnostics other than for medical or veterinary purposes]
Goods and ServicesScientific and industrial research in particular in the biological, biochemical, diagnostic and pharmaceutical fields; biochemistry and pharmaceutical laboratory services; scientific and technological services, namely, scientific research, analysis, testing, in particular in the biological, biochemical, diagnostic and pharmaceutical fields; industrial research and analysis, namely, services in development of biological, biochemical, pharmaceutical and diagnostic products; research for the identification and further development of biological, biochemical, pharmaceutical and diagnostic products

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status CodeG - NOT AVAILABLE
Class Status DateTuesday, May 17, 2022
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status CodeG - NOT AVAILABLE
Class Status DateTuesday, May 17, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, December 8, 2014
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameScil Proteins GmbH
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressDE

Party NameScil Proteins GmbH
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDE

Party NameScil Proteins GmbH
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDE

Trademark Events


Event DateEvent Description
Monday, December 8, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 8, 2014ASSIGNED TO EXAMINER
Monday, December 8, 2014NON-FINAL ACTION WRITTEN
Tuesday, December 9, 2014NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, December 10, 2014REFUSAL PROCESSED BY MPU
Wednesday, December 10, 2014NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, December 12, 2014APPLICATION FILING RECEIPT MAILED
Saturday, December 27, 2014REFUSAL PROCESSED BY IB
Wednesday, June 10, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, June 17, 2015ASSIGNED TO LIE
Wednesday, June 24, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, June 24, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 6, 2015EXAMINERS AMENDMENT -WRITTEN
Monday, July 6, 2015EXAMINERS AMENDMENT E-MAILED
Monday, July 6, 2015NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, July 6, 2015EXAMINER'S AMENDMENT ENTERED
Tuesday, July 7, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 8, 2015LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, July 22, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, August 5, 2015NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, August 5, 2015NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, August 11, 2015PUBLISHED FOR OPPOSITION
Tuesday, August 11, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Friday, August 21, 2015NOTIFICATION PROCESSED BY IB
Tuesday, October 27, 2015REGISTERED-PRINCIPAL REGISTER
Wednesday, January 27, 2016FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, May 12, 2016FINAL DISPOSITION PROCESSED
Thursday, May 12, 2016FINAL DISPOSITION NOTICE SENT TO IB
Friday, July 15, 2016FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, October 27, 2020COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Tuesday, October 26, 2021TEAS SECTION 71 RECEIVED
Tuesday, May 10, 2022CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, May 17, 2022REGISTERED - PARTIAL SEC 71 ACCEPTED
Tuesday, May 17, 2022NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Tuesday, January 17, 2023PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Thursday, March 9, 2023INVALIDATION PROCESSED
Thursday, March 9, 2023PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Sunday, April 30, 2023PARTIAL INVALIDATION PROCESSED BY THE IB
Friday, May 24, 2024INTERNATIONAL REGISTRATION RENEWED
Monday, October 28, 2024COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Thursday, December 4, 2014SN ASSIGNED FOR SECT 66A APPL FROM IB